Asymptomatic reactivation of JC virus in patients treated with  natalizumab.
De Gascun
Cillian F
CF
Lonergan
Roisin M
RM
Hall
William W
WW
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology; D007577:JC Virus / Q000302:isolation & purification* / Q000502:physiology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D012367:RNA, Viral / Q000097:blood / Q000652:urine; D019562:Viral Load; D014766:Viremia; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D012367:RNA, Viral; D039441:Integrin alpha4